In a series of recent webinars, the Ratcliffe Cardiology platform brings together European opinion leaders in interventional cardiology to comment on the 2024 ESC recommendations on the management of chronic coronary syndrome. Dr Patrick Serruys introduces this session in a dedicated webinar.
The Ratcliffe Cardiology platform recently published a series of webinars dedicated to the 2024 recommendations of the European Society of Cardiology (ESC) on the management of chronic coronary syndrome.
A series of webinars to explain the 2024 ESC recommendations on the management of chronic coronary syndrome
This series aims to provide professionals in the interventional cardiology industry with the latest clinical strategies and practical tools to integrate FFRct and coronary CT into workflows for effective management of coronary artery disease. The presentation webinar was entrusted to a global opinion leader in the specialty, Dr Patrick Serruys, who highlights the advantages provided by CT in the diagnosis and monitoring of chronic coronary syndrome.
Here it takes up the new ESC CCS guidelines which endorse CT technology for the evaluation of the coronary arterial lumen, the composition of the wall, in particular the possible presence of calcifications, or the cardiac functional significance of arterial narrowing by FFRct .
The coroscanner at the basis of diagnostic and therapeutic monitoring technology
FFRct is therefore subject to a class II recommendation in general and a class I recommendation for patients at higher risk. Coroscan therefore continues to be recognized as a Class I examination for patients with suspected coronary artery disease, which closely aligns with the American Scientific Societies (AHA – ACC) guidelines on chest pain.
These expert-led webinars, including interviews with thought leaders, comprehensively address the clinical implications for treatment decision-making and therapeutic monitoring. Access Dr Serruys’ comment by clicking on the image opposite.
Bruno Benque
